Rexin-G

Drug Profile

Rexin-G

Alternative Names: Retroviral Expression Vectors Bearing Inhibitory Genes; Rexin-G; Targeted nanomedicine; Tumour-targeted gene therapy vector - Epeius

Latest Information Update: 29 Jun 2015

Price : $50

At a glance

  • Originator Epeius Biotechnologies
  • Developer Epeius Biotechnologies Corporation
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteosarcoma; Soft tissue sarcoma; Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Marketed Solid tumours
  • Discontinued Breast cancer; Osteosarcoma; Pancreatic cancer; Soft tissue sarcoma

Most Recent Events

  • 02 Jun 2010 Efficacy and adverse event data from the phase II portion of a phase I/II trial in chemotherapy-resistant bone and soft tissue sarcoma released by Epeius Biotechnologies
  • 24 May 2010 Efficacy and adverse events data from a phase I/II trial in Pancreatic cancer released by Epeius Biotechnologies
  • 24 May 2010 Pharmacodynamics data from a phase I/II trial in Cancer released by Epeius Biotechnologies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top